Arrowhead Research traded at $63.59 this Friday February 20th, decreasing $0.27 or 0.42 percent since the previous trading session. Looking back, over the last four weeks, Arrowhead Research lost 5.93 percent. Over the last 12 months, its price rose by 219.55 percent. Looking ahead, we forecast Arrowhead Research to be priced at 61.62 by the end of this quarter and at 56.06 in one year, according to Trading Economics global macro models projections and analysts expectations.
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.